Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Neoplasms
  • Organoplatinum Compounds
  • Renal Insufficiency

abstract

  • Satraplatin PKs was altered in patients with renal impairment. However, a corresponding increase in satraplatin-related toxic effects was not observed.

publication date

  • April 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdr358

PubMed ID

  • 21828377

Additional Document Info

start page

  • 1037

end page

  • 44

volume

  • 23

number

  • 4